Coronary Angiography: Access, Technique, Complications, and FFR Integration

Coronary Angiography: Access, Technique, Complications, and FFR Integration

A practical procedural guide on radial-first access, catheter selection, FFR/iFR thresholds, contrast nephropathy prevention, and complication management.

Procedure Overview

Coronary angiography is the reference standard for coronary artery anatomy assessment, performed via percutaneous arterial access (radial preferred, femoral alternative) with selective contrast injection through preformed catheters. Modern practice integrates physiologic assessment with fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) for intermediate lesions, intravascular imaging for complex anatomy, and contrast-induced nephropathy prevention through pre-procedural hydration. Radial-first approach reduces major bleeding by 28% and mortality in ACS per MATRIX trial. Common indications include stable angina with positive non-invasive testing, acute coronary syndromes, sudden cardiac death survivors, ventricular arrhythmias, heart failure of unknown etiology, and pre-operative assessment before non-coronary cardiac surgery.

95%+Radial access success rate (modern)
≤0.80FFR threshold for revascularization
28%Bleeding reduction with radial (MATRIX)
1-3%Major complication rate

1. Indications and Pre-Procedural Assessment

Class I Indications (ACC/AHA/SCAI)

Coronary angiography carries Class I recommendation in multiple high-acuity scenarios where prompt anatomic definition guides revascularization decisions. ST-elevation myocardial infarction within 12 hours of symptom onset mandates emergent angiography with door-to-balloon time goal <90 minutes for primary PCI per the ACC/AHA STEMI guidelines. Non-ST-elevation acute coronary syndrome with high-risk features (GRACE score >140, refractory angina, hemodynamic instability, dynamic ECG changes, ventricular arrhythmias, mechanical complications) warrants invasive strategy within 24 hours. Cardiac arrest survivors with shockable rhythms or evidence of ongoing ischemia benefit from immediate angiography per the COACT trial subgroup analysis.

Stable ischemic heart disease indications include progressive symptoms despite optimal medical therapy, high-risk findings on non-invasive testing (large reversible perfusion defect, multi-territory ischemia, exercise-induced hypotension, summed stress score >8 on SPECT, ischemia >10% on stress imaging), and pre-operative evaluation before high-risk non-cardiac surgery in patients with multiple risk factors. The ISCHEMIA trial (Maron NEJM 2020) established that initial conservative strategy is non-inferior for stable patients without left main disease, but persistent symptoms or progressive ischemia remain Class I indications.

Mehran Score for Contrast-Induced Nephropathy Risk

Risk FactorPointsRisk Stratification
Hypotension (SBP <80 mmHg ≥1 hr)5≤5: 7.5% CIN, 0.04% dialysis
6-10: 14% CIN, 0.12% dialysis
11-15: 26% CIN, 1.09% dialysis
≥16: 57% CIN, 12.6% dialysis
IABP use5
Congestive heart failure (NYHA III-IV)5
Age >75 years4
Anemia (Hct <39 men, <36 women)3
Diabetes mellitus3
Contrast volume per 100 mL1
eGFR 40-60 mL/min/1.73m²2
eGFR <40 mL/min/1.73m²4-6

Anticoagulation Management

Warfarin should be withheld 5 days before elective angiography with bridging anticoagulation reserved for very high thromboembolic risk (mechanical mitral valve, recent VTE within 3 months, CHA₂DS₂-VASc ≥7 with prior stroke). The BRIDGE trial (Douketis NEJM 2015) demonstrated no benefit and increased bleeding with routine bridging in atrial fibrillation patients. Direct oral anticoagulants are held 24-48 hours pre-procedure depending on renal function—apixaban and rivaroxaban 24 hours if CrCl >50 mL/min and 48 hours if CrCl 30-50; dabigatran 48 hours if CrCl >50 and 96 hours if CrCl 30-50.

Antiplatelet therapy with aspirin 81-325 mg PO daily is continued through the procedure for all coronary angiography. P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) are continued for ACS patients but typically held 5-7 days before elective surgery if PCI is planned without immediate surgical backup needed. Metformin should be held 48 hours before contrast administration in patients with eGFR <60 mL/min/1.73m² and resumed only after creatinine recheck confirms preserved renal function.

2. Equipment and Catheter Selection

Diagnostic Coronary Catheter Shapes Comparison of Judkins Left, Judkins Right, Amplatz Left, and multipurpose catheters with their corresponding coronary ostia targets. Diagnostic Catheter Selection by Ostium Judkins Left (JL) Targets: LM ostium Judkins Right (JR) Targets: RCA ostium Amplatz Left (AL) Anomalous origins Tiger / Jacky Radial both ostia Standard sizes: JL 4.0, JR 4.0 femoral; Tiger 5 Fr radial
Figure 2.1 — Diagnostic coronary catheter shapes and target ostia.

Sheath Selection

Modern radial diagnostic angiography uses 5-6 Fr hydrophilic sheaths (e.g., Glidesheath Slender) with reduced outer diameter to minimize radial artery occlusion and spasm. The TALENT trial (Aminian EuroIntervention 2017) demonstrated significantly lower radial artery occlusion with thin-walled sheaths (1.6% vs 5.2%) without compromising support. Femoral access typically employs 6-7 Fr sheaths for diagnostic procedures, with larger sizes (7-8 Fr) reserved for complex PCI or mechanical circulatory support. Long sheaths (45-90 cm) facilitate access to the ascending aorta in patients with tortuous iliofemoral anatomy or severe peripheral arterial disease.

Diagnostic Catheter Inventory

CatheterApproachTarget VesselStandard Size
Judkins Left (JL)FemoralLeft main coronary arteryJL 3.5 (short aorta), JL 4.0 (standard), JL 5.0 (dilated root)
Judkins Right (JR)FemoralRight coronary arteryJR 4.0 standard
Amplatz Left (AL)Femoral or radialAnomalous origins, dilated aortic rootAL 1, AL 2, AL 3
Amplatz Right (AR)FemoralAnomalous RCA, high-takeoff RCAAR 1, AR 2
TigerRadialBoth LM and RCA (single catheter)5 Fr standard
JackyRadialBoth LM and RCA (single catheter)5 Fr standard
Multipurpose (MP)FemoralSVG to RCA, anomalous RCAMP A1, MP A2
Right Coronary Bypass (RCB)FemoralSVG to RCARCB
Left Coronary Bypass (LCB)FemoralSVG to LAD/CxLCB
Internal Mammary (IM)Left radial or femoralLIMA graftIM

Contrast Agent Selection

Iso-osmolar (iodixanol, 290 mOsm/kg) and low-osmolar non-ionic contrast agents (iohexol, iopamidol, ~600-800 mOsm/kg) are equivalent for routine diagnostic angiography. The CARE trial (Solomon JACC 2007) and ICON registry suggested marginal benefit of iso-osmolar agents in chronic kidney disease, but more recent meta-analyses including PREDICT (Eng JACC 2016) found no significant difference. High-osmolar ionic contrast agents are obsolete due to higher rates of hemodynamic disturbance and patient discomfort. Total contrast volume should be minimized—target contrast volume to creatinine clearance ratio <3.7 (Gurm formula) to mitigate CIN risk in patients with eGFR <60.

Coronary Angiography — Coronary Anatomy Coronary artery diagram: Coronary Angiography — Coronary Anatomy Ao LMCA LAD LCX RCA DIAGONAL OBTUSE MARGINAL PDA Coronary Angiography — Coronary Anatomy
Coronary Angiography — Coronary Anatomy

3. Step-by-Step Technique

Radial Access Protocol

Pre-procedure modified Allen test or Barbeau test confirms ulnar collateral patency, though contemporary practice has questioned the necessity of these tests as they have not demonstrated predictive value for hand ischemia after radial access (RADAR trial Bertrand JACC Intv 2014). Patient positioning involves arm abduction 30-45 degrees with wrist hyperextension over a wrist board. Sterile preparation with chlorhexidine and full barrier draping reduces infection risk. Local anesthesia with 1-2 mL of 1% lidocaine is administered subcutaneously over the radial artery 2-3 cm proximal to the styloid process.

Arterial access is achieved by either through-and-through technique (puncturing both walls and withdrawing to obtain pulsatile flow) or anterior wall puncture using a 21-gauge needle and 0.018-inch wire. Modified Seldinger technique with a 6 Fr hydrophilic sheath is then advanced. Intra-arterial cocktail administration includes heparin 5000 units for spasm prevention and thromboprophylaxis, plus verapamil 2.5-5 mg or nicardipine 200-400 mcg for spasm prophylaxis. The TEMURA trial demonstrated heparin alone is non-inferior to combination therapy for radial artery occlusion prevention.

Diagnostic catheter advancement uses 0.035-inch J-tip wire under fluoroscopic guidance through the radial artery, brachial artery, axillary artery, and into the ascending aorta. Catheter exchange should be performed over the wire to prevent loss of access. Catheter manipulation requires gentle counterclockwise rotation for left coronary engagement and clockwise rotation for right coronary engagement, with the catheter tip positioned at the appropriate aortic sinus.

Femoral Access Protocol

Common femoral artery puncture targets the segment between the inguinal ligament and the femoral bifurcation, optimally over the femoral head for effective post-procedural compression. Fluoroscopic landmarking using the inferior border of the femoral head as the target identifies the common femoral artery position. Ultrasound-guided puncture (FAUST trial Seto JACC Intv 2010) reduces vascular complications and number of attempts but has not demonstrated reduction in major complications.

Single-wall puncture technique using an 18-gauge needle at 30-45 degree angle, advancing slowly until pulsatile flow is achieved. Floor of the needle should be aspirated for arterial blood. The 0.035-inch J-tip wire is advanced into the iliac artery under fluoroscopy, followed by sheath placement. Femoral angiography after sheath placement confirms appropriate puncture site for safe vascular closure device deployment and identifies potential anatomic concerns (high bifurcation, atherosclerosis, anatomic variations).

Selective Engagement and Standard Angiographic Views

Left coronary artery engagement is achieved by advancing the JL 4.0 catheter into the ascending aorta until the catheter tip naturally engages the left main ostium with a characteristic "pop" sensation. Test injection of 1-2 mL contrast confirms ostial engagement and patency. Standard left coronary views include: RAO 30° caudal 30° (LAD bifurcation, ramus), RAO 30° cranial 30° (mid-distal LAD, diagonals), LAO 60° caudal 30° (left main, LCx ostium, "spider view"), LAO 60° cranial 20° (proximal-mid LAD, septal-diagonal separation), AP cranial 30° (LAD-D1 separation), and AP caudal 30° (LM bifurcation).

Right coronary artery engagement uses the JR 4.0 catheter with clockwise rotation in the right coronary sinus. Standard RCA views include: LAO 30° (proximal and mid RCA), RAO 30° (mid and distal RCA, posterolateral branches), LAO 30° cranial 30° (PDA, posterolateral branches, AV nodal artery), and AP cranial 30° (PDA bifurcation). Each injection should fully opacify the vessel for 3-4 cardiac cycles to assess flow, collateral filling, and washout pattern.

Saphenous Vein and Arterial Bypass Graft Engagement

SVG to RCA grafts originate from the right anterolateral aspect of the ascending aorta, engaged with multipurpose, right Judkins, or RCB catheters in shallow LAO projection. SVG to LAD/Cx grafts originate from the left anterolateral aspect, engaged with LCB, AL 1-2, or right Judkins catheters. LIMA grafts require dedicated IM catheter access, ideally via left radial approach (avoiding subclavian tortuosity from right access). The IM catheter is advanced through the left subclavian artery with the tip directed inferiorly to engage the LIMA origin. RIMA grafts are engaged similarly via right radial or femoral approach.

Coronary Angiography — Timeline Timeline: Coronary Angiography — Timeline 1 Step 1: Pre-procedure NPO 4h; INR &lt;2.0 if warfarin; hold metformin morning of (lactic aci 2 Step 2: Allen test + access Confirm dual radial/ulnar supply; sterile prep right radial; lidocaine 3 Step 3: Engage left coronary 5-6 Fr JL4 (or radial-specific) catheter over wire to ascending aorta; 4 Step 4: LAD/LCx images Standard views: AP cranial (LAD mid-distal), AP caudal (LM + LCx ostia 5 Step 5: Engage right coronary JR4 catheter; counterclockwise rotation; views: LAO 45 (RCA in plane), 6 Step 6: Physiology (if indicated) FFR pressure wire across intermediate stenosis (50-70%); hyperemia wit 7 Step 7: Closure + recovery Radial: TR Band hemostasis 2h; femoral: manual or vascular closure dev
Coronary Angiography — Timeline

4. Physiologic Assessment: FFR, iFR, and Resting Indices

Fractional Flow Reserve (FFR)

Fractional flow reserve is defined as the ratio of maximal achievable blood flow in a stenotic artery to the maximal achievable flow in the same artery without stenosis. The FFR threshold of ≤0.80 indicates hemodynamically significant stenosis warranting revascularization, established by the FAME trial (Tonino NEJM 2009) demonstrating 30% reduction in MACE with FFR-guided versus angiography-guided PCI. The FAME 2 trial (De Bruyne NEJM 2012) confirmed superiority of FFR-guided PCI plus optimal medical therapy over OMT alone for FFR ≤0.80 lesions in stable CAD.

FFR measurement requires maximal hyperemia induced by intravenous adenosine 140 mcg/kg/min via central or large peripheral vein, or intracoronary adenosine bolus 100-200 mcg for left coronary or 50-100 mcg for right coronary. Pressure wire is advanced distal to the stenosis with pullback recording during steady-state hyperemia. The pressure ratio is calculated as Pd/Pa where Pd is distal coronary pressure and Pa is aortic pressure. Common pitfalls include drift, pressure damping, and inadequate hyperemia—drift >0.03 requires recalibration and re-measurement.

Instantaneous Wave-Free Ratio (iFR)

iFR measures pressure ratio during the diastolic wave-free period (last 75% of diastole) when microvascular resistance is naturally minimized, eliminating the need for adenosine. The iFR threshold is ≤0.89 for hemodynamically significant stenosis. The DEFINE-FLAIR (Davies NEJM 2017) and iFR-SWEDEHEART (Götberg NEJM 2017) trials randomized over 4,500 patients and demonstrated non-inferiority of iFR-guided versus FFR-guided revascularization for 1-year MACE (6.8% vs 7.0% in DEFINE-FLAIR), with reduced procedure time, patient discomfort, and adenosine cost.

The "gray zone" between iFR 0.89 and 0.93 represents an area where adenosine-induced FFR may provide additional discrimination, though this practice has been challenged by hybrid iFR-FFR strategies. Resting full-cycle ratio (RFR), diastolic pressure ratio (dPR), and DFR (diastolic flow reserve) are equivalent non-hyperemic indices with the same ≤0.89 threshold validated in the VALIDATE-RFR registry.

IndexCutoffHyperemia RequiredValidation Trial
FFR≤0.80Yes (adenosine)FAME, FAME 2
iFR≤0.89NoDEFINE-FLAIR, iFR-SWEDEHEART
RFR≤0.89NoVALIDATE-RFR
dPR≤0.89NoRESOLVE
QFR (angiography-derived)≤0.80NoFAVOR III

Indications for Physiologic Assessment

Physiologic assessment is recommended for intermediate angiographic stenosis (40-70% diameter stenosis) where the hemodynamic significance is uncertain. The 2021 ACC/AHA Coronary Revascularization Guidelines provide Class I recommendation for FFR or iFR-guided PCI in stable CAD with intermediate stenoses. Multivessel disease with intermediate lesions benefits from physiologic assessment to identify culprit lesions—the FAME trial demonstrated that 35% of angiographically intermediate lesions are not hemodynamically significant and can be safely deferred. Left main intermediate stenosis assessment with FFR ≤0.80 or IVUS minimum lumen area <6.0 mm² (or 4.5 mm² for non-LMs) warrants revascularization.

Assessment after PCI for residual ischemia (post-PCI FFR ≥0.92 associated with optimal long-term outcomes per TARGET-FFR trial), serial lesions in the same vessel using pressure pullback, and assessment of bypass graft hemodynamics are additional applications. The FAVOR III trial (Xu Lancet 2021) validated quantitative flow ratio (QFR) as an angiography-based physiologic assessment that does not require pressure wire, with QFR ≤0.80 predicting MACE reduction with PCI guidance.

5. Complications and Management

Vascular Complications

Major vascular complications occur in 1-3% of femoral access procedures and <1% of radial procedures. Pseudoaneurysm presents as pulsatile, expansile mass with audible bruit on auscultation, typically 2-3 days post-procedure. Diagnostic ultrasound demonstrates "yin-yang" flow pattern with neck and sac. Treatment of pseudoaneurysms ≥2 cm employs ultrasound-guided thrombin injection (95% success in single session), surgical repair for failed thrombin or infected pseudoaneurysm, or prolonged compression for small (<2 cm) lesions.

Arteriovenous fistula presents as continuous bruit at the access site, often asymptomatic and identified on routine ultrasound. Small fistulas may close spontaneously; larger or symptomatic fistulas require surgical or percutaneous coil closure. Retroperitoneal hematoma is the most feared femoral complication, presenting with hypotension, back/flank pain, and falling hemoglobin. CT abdomen confirms the diagnosis. Management includes volume resuscitation, blood transfusion, reversal of anticoagulation, and rare need for surgical evacuation or embolization.

Radial Artery Occlusion (RAO)

RAO occurs in 1-10% post-radial access, more common with larger sheaths, longer procedure duration, female sex, and inadequate intraprocedural anticoagulation. Prevention strategies include: heparin 5000 units IV during procedure, use of smaller hydrophilic sheaths (5-6 Fr), patent hemostasis (compression while maintaining radial flow assessed by pulse oximetry or ulnar compression), and limiting compression duration to 2-3 hours. Treatment of symptomatic RAO with hand pain or weakness includes prolonged compression therapy, anticoagulation with low molecular weight heparin enoxaparin 1 mg/kg SC q12h for 4-6 weeks, or oral anticoagulation. Asymptomatic RAO does not typically require treatment due to ulnar collateral flow.

Coronary Artery Dissection and Perforation

Catheter-induced ostial dissection occurs in <1% of diagnostic angiography, most commonly in the right coronary artery from aggressive catheter manipulation or deep engagement. Dissections are graded NHLBI A-F based on length, intraluminal filling defect, and flow impairment. Type A-B dissections (intimal flap, focal lumen filling defect) without flow impairment may be observed. Type C-F dissections (extraluminal contrast persistence, total or subtotal occlusion) require immediate stenting to seal the entry point and restore flow. Aortic dissection (rare, <0.02%) presents with chest/back pain and may extend retrograde from the ostium—immediate cardiothoracic surgery consultation is mandatory.

Coronary perforation is rare in diagnostic angiography (<0.1%) but more common in PCI (0.2-0.6%). Ellis classification: Type I (intramural crater without extravasation), Type II (pericardial or myocardial blush without contrast jet), Type III (frank extravasation with jet, ≥1 mm exit hole). Management is graded: Type I—observation; Type II—prolonged balloon inflation, reversal of anticoagulation; Type III—emergent covered stent (PK Papyrus, Graftmaster), emergent pericardiocentesis if tamponade physiology develops, surgical repair as last resort. Distal wire perforation may require coil embolization, fat or microsphere injection.

Contrast-Induced Nephropathy (CIN)

CIN is defined as ≥0.3 mg/dL or ≥50% increase in serum creatinine within 48-72 hours of contrast exposure. Pathophysiology involves direct tubular toxicity, vasoconstriction, and oxidative stress. Risk factors include pre-existing CKD (eGFR <60), diabetes, advanced age, hemodynamic instability, anemia, and high contrast volume. Mehran score stratifies risk pre-procedurally.

CIN Prevention Bundle

  • Pre-procedural hydration: Isotonic saline 1-1.5 mL/kg/hr IV starting 6-12 hours before through 6-12 hours after contrast (POSEIDON, AMACING)
  • Contrast minimization: Target contrast volume / CrCl ratio <3.7 (Gurm formula); use iso-osmolar or low-osmolar agents
  • Hold nephrotoxins: NSAIDs, ACE inhibitors/ARBs (controversial, individualize), aminoglycosides, metformin (if eGFR <60)
  • NOT recommended: N-acetylcysteine, sodium bicarbonate (PRESERVE trial Weisbord NEJM 2018 showed no benefit), forced diuresis without volume replacement, dopamine, fenoldopam
  • For severe CKD (eGFR <30): Multidisciplinary discussion, consider RenalGuard system (matched fluid replacement to urine output), avoid contrast if possible (CO2 angiography for peripheral)

Other Complications

ComplicationIncidenceRecognitionManagement
Death0.08-0.14%Cardiac arrest, hemodynamic collapseACLS, mechanical circulatory support
Stroke0.05-0.1%Acute neurologic deficit, mental status changeEmergent neuroimaging, NIH stroke scale, possible thrombectomy
MI0.05%Chest pain, ECG changes, troponin riseIdentify and treat culprit, rule out coronary dissection
Arrhythmia (VT/VF)0.5%ECG monitor, hemodynamic instabilityACLS, consider catheter-induced ischemia or contrast effect
Anaphylactoid reaction0.5-3%Urticaria, bronchospasm, hypotensionEpinephrine 0.3-0.5 mg IM, diphenhydramine, methylprednisolone, IV fluids
Atheroembolism0.5-3%Livedo reticularis, blue toe syndrome, AKISupportive care, statin, rule out CIN

When to Refer or Escalate

Immediate cardiothoracic surgery consultation: acute Type A aortic dissection extending from coronary angiography, coronary perforation Type III with hemodynamic instability, acute mechanical complication of MI (papillary muscle rupture, VSD, free wall rupture). Vascular surgery consultation: rapidly expanding pseudoaneurysm, retroperitoneal hematoma with ongoing bleeding, infected pseudoaneurysm, severe limb ischemia from access site complication. Nephrology consultation: oliguric AKI with creatinine doubling, suspected need for renal replacement therapy, atheroembolic disease with multi-organ involvement.

Coronary Angiography — Coronary Anatomy Coronary artery diagram: Coronary Angiography — Coronary Anatomy Ao LMCA LAD LCX RCA DIAGONAL OBTUSE MARGINAL PDA Coronary Angiography — Coronary Anatomy
Coronary Angiography — Coronary Anatomy

6. Post-Procedure Care and Follow-Up

Hemostasis and Sheath Removal

Radial sheath removal occurs at procedure conclusion with placement of TR Band, Hemoband, or similar pneumatic compression device. Patent hemostasis technique—gradually deflating compression while monitoring radial flow with pulse oximetry on the ipsilateral thumb—reduces RAO by maintaining anterograde flow. Compression duration of 2-3 hours followed by gradual release over 30-60 minutes is standard. The PROPHET trial demonstrated patent hemostasis significantly reduces RAO (5.0% vs 12.0%) compared to occlusive compression.

Femoral sheath removal can be performed manually with 20-30 minutes of direct pressure, or using vascular closure devices (VCDs). VCD options include collagen-based plugs (Angio-Seal), suture-mediated devices (Perclose ProGlide), and topical hemostatic patches (D-Stat). The CLOSURE-FAST registry suggested VCDs reduce time to ambulation but did not significantly reduce vascular complications. Manual compression followed by 4-6 hours of bedrest with leg straight is standard for diagnostic procedures; PCI or larger sheath sizes may require longer immobilization.

Discharge Criteria and Activity Restrictions

Same-day discharge after diagnostic angiography is appropriate for stable patients without complications, with adequate hemostasis, ambulation tolerance, and home support. Patients should be observed minimum 4-6 hours post-procedure. Discharge criteria include: stable vital signs, no chest pain or new symptoms, no access site bleeding or hematoma, intact distal pulses, ability to ambulate, stable renal function (if baseline CKD), and reliable home support and access to emergency care.

Discharge Instructions

  • Activity: No heavy lifting (>10 lbs) for 24-48 hours post-radial, 5-7 days post-femoral. No driving for 24 hours. Resume normal activities after 24-48 hours if no symptoms.
  • Wound care: Keep access site dry for 24 hours. Bandage may be removed after 24 hours. Shower OK after 24 hours; avoid bathtubs/swimming for 5-7 days.
  • Hydration: Drink at least 2-3 liters of fluid in the 24 hours post-procedure to facilitate contrast clearance.
  • Medications: Resume aspirin, antiplatelets as instructed. Resume metformin only after creatinine recheck at 48-72 hours. Resume warfarin or DOAC per cardiologist instructions.
  • Warning signs to seek emergency care: Severe access site bleeding not controlled by direct pressure, expanding hematoma, loss of pulse or cold extremity, severe back/flank pain, chest pain or pressure, shortness of breath, weakness or numbness, fever >38.5°C.

Follow-Up Laboratory Studies

Serum creatinine recheck at 48-72 hours post-procedure is recommended for patients with baseline CKD (eGFR <60), diabetes, or other CIN risk factors. Earlier recheck may be needed for high-risk patients or those with oliguria. Hemoglobin recheck may be appropriate for patients with significant access site complications, large contrast volumes, or known anemia. Patients with positive findings (ischemia, multivessel disease, valve disease) require coordinated follow-up with cardiology for treatment planning.

Pearl: Pulmonary Edema After Contrast

Patients with severe LV dysfunction (EF <30%) or critical aortic stenosis are at risk for acute pulmonary edema during contrast administration due to volume overload and contrast osmotic effects. Pre-procedural diuresis with IV furosemide for euvolemic CHF patients, careful contrast volume minimization, and immediate access to non-invasive ventilation can mitigate this complication. Consider intra-aortic balloon pump or Impella support for hemodynamically tenuous patients undergoing complex angiography.

Pitfall: Spasm Mistaken for Stenosis

Catheter-induced or focal coronary spasm, particularly at vessel ostia or during instrumentation, can mimic significant stenosis on angiography. Failure to recognize spasm leads to inappropriate stenting of normal vessels. When ostial or focal narrowing is observed, administer intracoronary nitroglycerin 100-200 mcg and repeat injection. True stenoses persist; spasm resolves with vasodilator. Right coronary spasm during JR catheter manipulation is particularly common—back off catheter, administer nitrates, and reassess.

7. Pearls, Pitfalls, and Frequently Asked Questions

Procedural Pearls

Pearl: Always Tip the Aortic Cusp

Before engaging the left main, always perform a non-selective injection in the left coronary cusp to confirm anatomy, identify ostial disease (left main or RCA ostial stenosis), and verify catheter position. This 2-3 mL contrast injection prevents catastrophic dissection from blind catheter advancement into ostial disease. The "cusp shot" reveals anomalous origins, ostial stenosis, and aortic root pathology that may modify procedure planning.

Pearl: Pressure Damping Means Trouble

Loss of pulse pressure waveform (damping) when engaging a coronary artery indicates that the catheter tip is occluding the vessel ostium or has wedged into a small branch. Continued contrast injection in this position causes dissection or rupture. Immediate withdrawal of the catheter, observation of pressure recovery, and reassessment of catheter position prevents catastrophic complication. Ostial RCA disease commonly causes damping with JR engagement—back off and use AL or smaller catheter for selective injection.

Pitfall: Inadequate Hyperemia During FFR

Inadequate hyperemia produces falsely elevated FFR values (false negative for ischemia). Causes include peripheral IV access for adenosine (use central or large peripheral vein), beta-blocker pretreatment blunting hyperemic response, microvascular dysfunction in diabetics or LVH patients, and caffeine intake within 12 hours. If FFR is borderline (0.78-0.85) and hyperemia appears blunted (Pa-Pd gradient narrow), repeat with intracoronary adenosine 200-400 mcg or use iFR which does not require hyperemia.

Pitfall: Underestimating Bifurcation Lesions

Single-projection assessment of bifurcation lesions consistently underestimates side branch ostial disease. Always assess bifurcation in two orthogonal projections (e.g., RAO caudal AND AP cranial for LAD-D1). Medina classification (1,1,1) versus (1,1,0) significantly impacts treatment strategy. IVUS or OCT is invaluable for bifurcation assessment and planning—particularly for left main bifurcation where DK crush, culotte, or T-stenting strategies require precise anatomic understanding.

8. Procedural Experience: Radial Access First, FFR for Equivocal Lesions

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Whichever sheath tray is already open on the table shapes access before anyone examines a wrist, and in the catheterization laboratory the operators who consistently get the cleanest outcomes are not the ones with the fastest fluoroscopy times but the ones with the most disciplined access and lesion-significance decisions. In the consulting role, the question to ask the cardiology team before any cirrhotic patient enters the cath lab is: "Radial first, and are we using the lowest-contrast strategy possible?"

Radial Access — Why Experienced Clinicians Push It Even in Difficult Anatomy

The MATRIX trial and meta-analyses established radial access as default — lower bleeding (especially in cirrhotic, anticoagulated, and elderly patients), lower mortality in ACS, and earlier ambulation. In the consult workflow, seasoned clinicians explicitly advocate radial first for any patient with INR >1.5, platelets <100, on DOAC or warfarin, or with prior groin complications. The "radial is harder" argument has weakened as operators have built experience; modern radial access has <5% crossover to femoral in trained hands. The bleeding cost of femoral default in these populations is too large to defer to operator preference.

The Contrast Discipline Experienced Practice Enforces for CKD Patients

Contrast-induced AKI is the most underappreciated DOPSS-equivalent complication in coronary angiography. For any patient with eGFR <60, experienced practice pushes for: total contrast volume ≤3.5 mL per mL/min of eGFR (the Mehran formula), iso-osmolar contrast (iodixanol) over low-osmolar, isotonic crystalloid hydration 1 mL/kg/h for 6-12 hours pre- and post-procedure, and N-acetylcysteine 1200 mg PO BID day-of and day-after only if convenient (modest evidence). The hardest negotiation is when "we need 30 mL more to image the LCx" pushes the patient over the Mehran threshold — experienced practitioners support deferring to a focused staged angiogram rather than completing in one session.

FFR/iFR — When Experienced Clinicians Insist On Physiologic Assessment

For intermediate stenoses (40-70% visual estimate), physiologic assessment before stenting is non-negotiable in experienced practice. FFR ≤0.80 indicates ischemia warranting intervention; iFR ≤0.89 is equivalent. The FAME 2 and DEFER trials demonstrated that FFR-guided revascularization improves outcomes versus angiographic-only assessment, with substantial reduction in unnecessary stenting. In the consulting role, seasoned clinicians challenge "this looks like 60%" decisions with "what's the FFR?" before signing off on the cath lab plan. Stenting an FFR-negative lesion is harm without benefit.

Post-Procedure Vascular Complication Watch

For femoral access patients (still common despite radial first), the complications experienced practitioners see consult on most are: retroperitoneal hematoma (the killer — falling Hgb without obvious external bleeding, hypotension, back pain), pseudoaneurysm (palpable pulsatile mass, bruit), AV fistula (continuous bruit), and access-site infection. The post-procedure orders include serial vital signs q15 min × 2h then q1h × 4h, Hgb at 4 and 8 hours post-procedure, and ultrasound for any neurovascular concern. The patient who develops back pain after femoral access at hour 4-6 is retroperitoneal bleed until proven otherwise.

Illustrative Scenario — Femoral Access in Cirrhotic Patient Caused Preventable Bleeding

A man in his late sixties with Child-Pugh B cirrhosis (platelets 78,000, INR 1.6) was scheduled for elective coronary angiography for chest pain workup. The treating clinicians were consulted pre-procedure for cirrhosis management; they documented radial-first preference in the chart and discussed with cardiology. The operating cardiologist preferred femoral access citing "tortuous radial in this patient last time" — femoral was performed with 6F sheath. At hour 5 post-procedure he developed back pain and hypotension to 88/55; Hgb had dropped from 11.8 to 7.9. CT abdomen showed retroperitoneal hematoma. He required 4 units PRBC, ICU admission, and 5-day prolonged stay. Right radial access on a subsequent staged procedure two weeks later (after recovery and platelet/INR optimization) was completed without complication. The femoral choice cost a preventable ICU admission.

Takeaway: cirrhotic patients with platelets under 100 and INR over 1.5 have femoral access bleeding complications that are simply not present with radial access. The "this radial was difficult last time" argument is rarely strong enough to overcome the bleeding risk. Pre-procedure radial-first advocacy from a non-cardiology consultant who has seen these complications has measurable impact on outcomes.

Procedural Adjustments to Standard Coronary Angiography

  1. Radial-first default, especially for high-bleeding-risk patients: INR >1.5, platelets <100, DOAC/warfarin, elderly, prior groin complications. Modern radial has <5% crossover; bleeding benefit is large.
  2. Mehran-formula contrast limit for eGFR <60: Total contrast ≤3.5 mL per mL/min of eGFR. Iso-osmolar agent preferred. Defer to staged angio if contrast pushes limit; complete imaging is not worth AKI.
  3. FFR/iFR for intermediate (40-70% visual) lesions before stenting: FFR ≤0.80 or iFR ≤0.89 indicates ischemia. Visual-estimate-only stenting of intermediate lesions causes net harm in FFR-negative cases. Push for physiologic assessment, not interventional reflex.
  4. Post-femoral access bleeding surveillance protocol: Vitals q15 min × 2h then q1h × 4h, Hgb at 4h and 8h, low threshold for CT abdomen with back pain or unexplained hypotension. Retroperitoneal hematoma kills via missed early signs.
Coronary Angiography: Access & Contrast Discipline Two-panel diagram: left panel access selection decision tree comparing radial and femoral approaches with high-bleeding-risk factors; right panel contrast-induced AKI prevention protocol with Mehran formula calculation and renal protection strategies Access Selection & Contrast-AKI Prevention Access Selection Decision Coronary angiogram planned High-bleeding-risk factors (any) • INR >1.5 or anticoagulated (DOAC, warfarin) • Platelets <100,000 • Age >75, prior groin complications, frail → Radial access STRONGLY preferred Radial Access (default) • Allen/modified Allen test or pulse oximetry • 5F-6F sheath, hydrophilic-coated MATRIX: less bleeding + mortality benefit in ACS Femoral Access (reserved) Tortuous radial after attempted crossover Large-bore sheaths needed (IABP, Impella) ⚠ Post-femoral surveillance Vitals q15min × 2h, Hgb at 4h + 8h, watch back pain Retroperitoneal hematoma: hypotension + back pain Contrast-AKI Prevention Risk stratification (eGFR-based) eGFR <60: high risk for CI-AKI eGFR <30: very high risk + consider alternatives Mehran formula — Contrast Volume Cap Maximum mL = 3.5 × eGFR (mL/min) eGFR 40 → max 140 mL contrast eGFR 25 → max 87 mL contrast Defer to staged angio if limit exceeded Hydration protocol Isotonic crystalloid 1 mL/kg/h × 6-12h pre Continue 6-12h post-procedure Contrast agent selection Iso-osmolar (iodixanol) over low-osmolar CO2 angiography in eGFR <30 where feasible Hold nephrotoxins pre-procedure Metformin, NSAIDs, ACEi/ARB if eGFR <30 Cr at 48-72h post for high-risk patients

Additional Operator Pearls

Beyond the standard pearls, several operator-level habits separate consistent excellence from average outcomes in coronary angiography. Recognizing engagement of the appropriate coronary ostium is sometimes ambiguous with anomalous origin variants — when the standard Judkins curve does not engage, switching to an Amplatz left 1 or 2 catheter usually addresses high-takeoff or anteriorly-displaced LCA origins rather than persisting with the Judkins. For RCA engagement in patients with horizontal aortic root (commonly elderly or hypertensive), the right Judkins 4 may need substitution with Judkins 5 or Amplatz right 1. Documenting catheter manipulation time is helpful for trainees — extended catheter dwell time at the coronary ostium correlates with downstream dissection risk, particularly in calcified ostia. Finally, the standard "do not power-inject into LMCA" warning is real and consequential: hand injection only for left main angiography, and the recognized signs of contrast staining outside the artery (perforation versus contained injection) demand immediate withdrawal and assessment.

Frequently Asked Questions

When should radial access be preferred over femoral access?
Radial access is the default first-line approach for both diagnostic angiography and PCI in stable and ACS patients per SCAI 2021 and ESC 2023 guidelines. The MATRIX trial (Valgimigli Lancet 2015) demonstrated 28% relative reduction in major bleeding (1.6% vs 2.3%) and significant reduction in all-cause mortality at 30 days (1.6% vs 2.2%) with radial access in ACS patients. Femoral access is reserved for failed radial attempts, severe radial artery disease, requirement for large-bore access (>7 Fr) such as Impella or IABP support, complex chronic total occlusion intervention requiring dual access, or anatomic considerations like prior CABG with bilateral mammary grafts requiring contralateral femoral approach for graft engagement.
What FFR and iFR thresholds define hemodynamically significant lesions?
Fractional flow reserve (FFR) ≤0.80 indicates hemodynamically significant stenosis warranting revascularization, validated by FAME (Tonino NEJM 2009) and FAME 2 (De Bruyne NEJM 2012) trials. FFR is measured during maximal hyperemia induced by adenosine 140 mcg/kg/min IV or intracoronary 100-200 mcg bolus. Instantaneous wave-free ratio (iFR) ≤0.89 is the equivalent threshold for the resting non-hyperemic period (DEFINE-FLAIR Davies NEJM 2017, iFR-SWEDEHEART Götberg NEJM 2017), eliminating need for adenosine and improving patient tolerance. Lesions with FFR 0.81-0.89 represent the deferral zone where medical therapy is non-inferior to PCI for major adverse cardiac events at 5 years.
How should contrast-induced nephropathy be prevented in high-risk patients?
Pre-procedural risk stratification with the Mehran score (age >75, hypotension, IABP, CHF, anemia, diabetes, contrast volume, eGFR) identifies patients at elevated risk. The cornerstone of prevention is intravenous isotonic saline 1-1.5 mL/kg/hr starting 6-12 hours before and continuing 6-12 hours after contrast exposure (POSEIDON Brar Lancet 2014, AMACING Nijssen Lancet 2017). Iso-osmolar (iodixanol) or low-osmolar contrast at minimum effective volume should be used—target contrast volume to creatinine clearance ratio <3.7 (Gurm JACC 2011). N-acetylcysteine and sodium bicarbonate are no longer routinely recommended after PRESERVE trial (Weisbord NEJM 2018) showed no benefit. Hold metformin 48 hours before in patients with eGFR <60 and recheck creatinine before resumption.
Which catheter shapes engage which coronary ostia?
Judkins Left (JL) 3.5 or 4.0 catheters preferentially engage the left main coronary ostium via femoral approach, with smaller curves (JL 3.5) for shorter aortas and larger curves (JL 4.0-5.0) for dilated aortic roots. Judkins Right (JR) 4.0 engages the right coronary artery (RCA) ostium with a clockwise rotation maneuver. Amplatz Left (AL) 1-2 provides better support for tortuous anatomy and engages anomalous left main from the right cusp. From radial access, Tiger or Jacky multipurpose catheters allow single-catheter engagement of both coronaries. For saphenous vein grafts, multipurpose or right Judkins are commonly used; left internal mammary artery (LIMA) grafts require an IM (internal mammary) catheter via left radial or femoral approach.
What are the absolute and relative contraindications to coronary angiography?
Absolute contraindications are limited and primarily relative in modern practice: patient refusal of consent and inability to cooperate. Relative contraindications include uncorrected severe coagulopathy with INR >2.0 (use radial to mitigate bleeding risk), severe uncontrolled hypertension (>180/110 mmHg), decompensated heart failure with pulmonary edema, severe electrolyte abnormalities (hypokalemia <3.0, hyperkalemia >6.0), active infection or fever >38.5°C, recent stroke within 1 month, severe contrast allergy without premedication, severe contrast-induced nephropathy risk with eGFR <30 not on dialysis, and active gastrointestinal bleeding. Pregnancy requires fetal shielding and minimization of fluoroscopy time but is not absolute contraindication when emergent (STEMI in pregnancy).
How are radial artery occlusion and pseudoaneurysm prevented and managed?
Radial artery occlusion (RAO) occurs in 1-10% post-radial access. Prevention strategies include patent hemostasis with the Barbeau test or oximetry-guided compression (RAUS technique—reduce, assess, until satisfactory), heparin 5000 units IV during procedure, and use of smaller sheath sizes (5-6 Fr default). Symptomatic RAO presents with hand pain, weakness, or cold sensation; most are asymptomatic due to ulnar collateral flow. Treatment includes prolonged compression therapy with low molecular weight heparin or oral anticoagulation for 4-6 weeks. Pseudoaneurysm at the femoral access site presents as pulsatile mass with bruit on auscultation; ultrasound-guided thrombin injection achieves closure in 95% within minutes. Surgical repair is reserved for failed thrombin injection, infected pseudoaneurysm, or compression of femoral nerve.
When is intravascular imaging (IVUS or OCT) indicated during angiography?
Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) provide cross-sectional imaging beyond luminography. IVUS-guided PCI reduces target lesion revascularization and major adverse cardiac events particularly for left main lesions (ULTIMATE Zhang JACC 2018, IVUS-XPL Hong JAMA 2015). OCT offers higher resolution (10-20 μm) for fibrous cap thickness, lipid pool detection, and stent strut apposition assessment (ILUMIEN III Ali Lancet 2016). Specific indications include: left main coronary artery assessment, ostial lesions, bifurcation lesions, ambiguous angiographic stenosis severity, suspected stent thrombosis or restenosis evaluation, mechanism of stent failure (under-expansion, malapposition, edge dissection), guidance of complex PCI including chronic total occlusion, and characterization of intermediate lesions when FFR/iFR is not available or non-conclusive.

Leave a Reply

Your email address will not be published. Required fields are marked *